Nautilus Biotechnology is trading 8.94% lower at $2.40, with no company-specific announcement identified to explain the October 20 decline.
- It closed at $2.63 on October 19, after a 27.67% rise that session.
- Its third-quarter results are scheduled for October 27.
- Biotech was reported higher while the Nasdaq was lower; that mixed backdrop does not establish a clear cause. Trading volume information was unavailable in the provided price context or search results.